Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $134,123.84 in Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 3,104 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total value of $134,123.84. Following the completion of the sale, the insider now owns 75,289 shares in the company, valued at $3,253,237.69. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Friday, September 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total transaction of $10,983.96.
• On Monday, August 5th, Dennis Cho sold 709 shares of Twist Bioscience stock. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37.

Twist Bioscience Stock Performance

Shares of TWST opened at $43.34 on Monday. The business’s fifty day moving average price is $44.94 and its two-hundred day moving average price is $43.75. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -12.90 and a beta of 1.77. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The firm had revenue of $81.50 million for the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The company’s revenue was up 27.7% compared to the same quarter last year. During the same period last year, the company earned ($1.01) EPS. As a group, research analysts forecast that Twist Bioscience Co. will post -3.13 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. EdgeRock Capital LLC bought a new stake in shares of Twist Bioscience during the second quarter worth approximately $43,000. Blue Trust Inc. boosted its stake in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience during the 2nd quarter worth $61,000. Nisa Investment Advisors LLC raised its position in shares of Twist Bioscience by 31.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after acquiring an additional 546 shares during the last quarter. Finally, CWM LLC lifted its stake in shares of Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares during the period.

Analyst Ratings Changes

Several analysts have recently weighed in on TWST shares. Robert W. Baird raised their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. TD Cowen raised their price target on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Barclays decreased their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $51.63.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.